Furthermore, [58] observed distinct proteomic alterations in the skeletal muscle of FA patients, indicating a broad spectrum of mitochondrial dysfunction, clearly also the Nrf2 pathway disruption, which is a target of newly approved FA treatment (omaveloxolone). This evidence concerns the gene NFE2L2 and Friedreich ataxia.